{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:25Z","timestamp":1790217385227,"version":"4.1.0"},"reference-count":69,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The aim of this study was to examine the incidence and severity of refractive errors that occur following the treatment of retinopathy of prematurity (ROP) with anti-vascular growth factor (anti-VEGF) agents and laser photocoagulation. Methods: A review of the literature using three databases (PubMed, Embase, Medline) was performed using appropriate search terms, and the results of the relevant studies were compiled and extracted for descriptive analysis. Results: Sixty articles were identified. The cohorts in the studies were treated with either anti-VEGF monotherapy, laser photocoagulation, or a combination, with a high prevalence of myopia, ranging from 0 to 47.7%. Refractive errors of myopia, hypermetropia, astigmatism, and anisometropia were considered in infants who received ocular interventions for ROP. Conclusions: In comparison to laser photocoagulation, anti-VEGF monotherapy appears to yield lower levels of myopia and anisometropia; however, the incidence of hypermetropia and astigmatism is variable among cohort groups treated with different anti-VEGF agents.<\/jats:p>","DOI":"10.3390\/jcm14030810","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T07:54:08Z","timestamp":1738050848000},"page":"810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-129X","authenticated-orcid":false,"given":"Amy T.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Queensland Children\u2019s Hospital, South Brisbane 4101, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Queensland Children\u2019s Hospital, South Brisbane 4101, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Queensland Children\u2019s Hospital, South Brisbane 4101, Australia"},{"name":"Faculty of Medicine, The University of Queensland, St Lucia 4067, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pertl, L., Steinwender, G., Mayer, C., Hausberger, S., P\u00f6schl, E.M., Wackernagel, W., Wedrich, A., El-Shabrawi, Y., and Haas, A. (2015). A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129383"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40942-023-00456-x","article-title":"Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment","volume":"9","author":"Asano","year":"2023","journal-title":"Int. J. Retin. Vitreous."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/pediatric16030069","article-title":"Preferred Treatment Patterns of Retinopathy of Prematurity: An International Survey","volume":"16","author":"Wang","year":"2024","journal-title":"Pediatr. Rep."},{"key":"ref_5","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis","volume":"69","author":"Martorell","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_8","first-page":"49","article-title":"Ocular effects of intravitreal anti-vascular endothelial growth factor (ranibizumab) for retinopathy of prematurity attending tertiary hospital in Oman: Cross-sectional study","volume":"34","year":"2019","journal-title":"Oman Med. J."},{"key":"ref_9","first-page":"1079","article-title":"Comparison of Complications of Intravitreal Bevacizumab with Laser Photocoagulation for the Treatment of Retinopathy of Prematurity","volume":"12","author":"Arfat","year":"2018","journal-title":"Pak. J. Med. Health Sci. 2018"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/ICU.0000000000000783","article-title":"Complications of retinopathy of prematurity treatment","volume":"32","author":"Barnett","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s10792-022-02321-6","article-title":"Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: The importance of retinal vascularization","volume":"42","author":"Bayramoglu","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.4103\/ijo.IJO_243_22","article-title":"Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab","volume":"70","author":"Bayramoglu","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"ref_15","first-page":"4565216","article-title":"Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age","volume":"2018","author":"Chen","year":"2018","journal-title":"J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and Functional Results of Intravitreal Aflibercept Monotherapy for Type 1 Retinopathy of Prematurity: One-Year Outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s00431-023-04965-7","article-title":"Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity","volume":"182","author":"Cheng","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s00417-022-05730-6","article-title":"Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: Systemic review and a 17-year longitudinal study","volume":"260","author":"Chou","year":"2022","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-021-01922-2","article-title":"The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review","volume":"36","author":"Chow","year":"2022","journal-title":"Eye"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","article-title":"Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity","volume":"138","author":"Crouch","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_21","first-page":"545","article-title":"Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity","volume":"55","author":"Karapapak","year":"2021","journal-title":"Sisli Etfal Hast. Tip. Bul."},{"key":"ref_22","first-page":"384","article-title":"Long-term Visual and Refractive Outcomes of Argon Laser-treated Retinopathy of Prematurity","volume":"17","author":"Farvardin","year":"2022","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2021.11.015","article-title":"Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity","volume":"238","author":"Gundlach","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","article-title":"Early Refractive Outcome After Intravitreous Bevacizumab for Retinopathy of Prematurity","volume":"130","author":"Harder","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: Refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jaapos.2022.08.085","article-title":"Outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","volume":"26","author":"Holt","year":"2022","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jaapos.2022.08.524","article-title":"Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","volume":"26","author":"Hoppe","year":"2022","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hwang, E.S., Kassem, I.S., Allozi, R., Kravets, S., Al-Kirwi, K.Y., Hallak, J.A., and Costakos, D.M. (2022). Association between myopia progression and quantity of laser treatment for retinopathy of prematurity. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279898"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcjo.2022.07.001","article-title":"Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: A Canadian experience","volume":"58","author":"Isaac","year":"2023","journal-title":"Can. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101097","DOI":"10.1016\/j.ajoc.2021.101097","article-title":"Ten-year outcomes after initial management with laser photocoagulation versus intravitreal bevacizumab injection in a pair of identical twins with aggressive posterior retinopathy of prematurity","volume":"22","author":"Jeon","year":"2021","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/ojo.ojo_315_21","article-title":"Refractive outcomes following yttrium aluminum garnet laser (532 nm green laser) in severe retinopathy of prematurity","volume":"15","author":"Jossy","year":"2022","journal-title":"Oman J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.jaapos.2022.08.089","article-title":"Refractive outcomes of patients treated for retinopathy of prematurity","volume":"26","author":"Khan","year":"2022","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e042384","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: A meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000439182","article-title":"Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy","volume":"234","author":"Kuo","year":"2015","journal-title":"Ophthalmologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Linghu, D., Cheng, Y., Zhu, X., Deng, X., Yin, H., Jiang, Y., Zhao, M., Li, X., and Liang, J. (2022). Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1627 Eyes in China. Front. Med., 9.","DOI":"10.3389\/fmed.2022.911095"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s00417-022-05663-0","article-title":"Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection","volume":"260","author":"Lu","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): Prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Schwartz","year":"2013","journal-title":"Retina"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10384-022-00921-4","article-title":"Risk factors for early-onset high myopia after treatment for retinopathy of prematurity","volume":"66","author":"Matsumura","year":"2022","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cxo.13019","article-title":"Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity","volume":"103","author":"Meng","year":"2020","journal-title":"Clin. Exp. Optom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/EB.S99306","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Geloneck","year":"2016","journal-title":"Eye Brain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1038\/s41433-023-02559-z","article-title":"Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: A multicentre study from J-CREST group","volume":"37","author":"Murakami","year":"2023","journal-title":"Eye"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.4103\/ijo.IJO_1209_22","article-title":"Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity","volume":"71","author":"Pawar","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/09273972.2019.1697302","article-title":"Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP)","volume":"28","author":"Shoeibi","year":"2020","journal-title":"Strabismus"},{"key":"ref_50","first-page":"386","article-title":"Functional results in children with retinopathy of prematurity treated with intravitreal bevacizumab","volume":"98","year":"2023","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_51","first-page":"6539","article-title":"Aggressive Posterior Retinopathy Of Prematurity: Functional Outcomes Following Intravitreal Bevacizumab","volume":"60","author":"Rubino","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_53","first-page":"2161","article-title":"Long term visual and neurodevelopmental outcomes in ROP patients treated with laser photocoagulation versus intravitreal anti-VEGF therapy","volume":"61","author":"Hawn","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.10.4.14","article-title":"Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity","volume":"10","author":"Simmons","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Spiller, A., Verkuil, L., Forbes, B., Yu, Y., Ying, G.-S., and Binenbaum, G. (2022). Refractive outcomes after primary bevacizumab followed by laser versus primary laser alone for Retinopathy of Prematurity. Investig. Ophthalmol. Vis. Sci., 63.","DOI":"10.1016\/j.jaapos.2022.08.126"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"Erol","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tan, Q.-Q., Christiansen, S.P., Wang, J., and Tsai, D.-C. (2019). Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225643"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3928\/01913913-20120731-03","article-title":"Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab","volume":"49","author":"Tseng","year":"2012","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: A systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaapos.2022.08.042","article-title":"Two-year ocular and developmental outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity","volume":"26","author":"Wallace","year":"2022","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10.e1","DOI":"10.1016\/j.jaapos.2022.11.020","article-title":"Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity","volume":"27","author":"Wallace","year":"2023","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_62","unstructured":"Wiecek, E.K., Akula, J., Vanderveen, D., Mantagos, I., Wu, C., Curran, A.-L., and Fulton, A.B. (2022). Development of Anisometropic Amblyopia in Children treated for Type I Retinopathy of Prematurity. Investig. Ophthalmol. Vis. Sci., 63."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajo.2022.03.020","article-title":"Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation","volume":"240","author":"Wiecek","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1038\/s41433-022-02375-x","article-title":"Corneal topography in preterm children aged 2 years to 12 years with or without retinopathy of prematurity","volume":"37","author":"Wu","year":"2023","journal-title":"Eye"},{"key":"ref_65","first-page":"1453","article-title":"Development of myopia in laser-treated ROP infants: Prematurity or laser photocoagulation?","volume":"43","author":"Kara","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_66","first-page":"2197","article-title":"One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity","volume":"43","author":"Kara","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joco.2018.10.008","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity","volume":"31","author":"Roohipoor","year":"2019","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_68","first-page":"Cd009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"2","author":"Sankar","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/bjophthalmol-2015-307724","article-title":"Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: Implications for aetiology and early prevention","volume":"100","author":"Rudnicka","year":"2016","journal-title":"Br. J. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:35Z","timestamp":1759919795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030810"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030810","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}